| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T154 |
0-25 |
Sentence |
denotes |
5 Recombinant type I IFN |
| T155 |
27-83 |
Sentence |
denotes |
5.1 Hypothesis: IFNs play a role in anti-viral immunity |
| T156 |
84-257 |
Sentence |
denotes |
Type I IFNs play a primary role in the inhibition of viral replication through the coordination of anti-viral immune responses and modulation of inflammatory responses [24]. |
| T157 |
259-273 |
Sentence |
denotes |
5.2 Rational: |
| T158 |
274-342 |
Sentence |
denotes |
Recombinant type I IFN can effectively inhibit SARS-CoV2 replication |
| T159 |
343-531 |
Sentence |
denotes |
In 24–48 h after infection, SARS-CoV2 replication reaches titer that causes the cytopathic effect in Vero E6 cells, which express ACE2 and thus are susceptible to SARS-CoV2 infection [25]. |
| T160 |
532-598 |
Sentence |
denotes |
It is similar to the viral replication kinetics for SARS-CoV [25]. |
| T161 |
599-729 |
Sentence |
denotes |
Pretreatment with recombinant type I IFN could effectively inhibit SARS-CoV2 replication at both 24 and 48 h after infection [25]. |
| T162 |
730-819 |
Sentence |
denotes |
For SARS-CoV, such an effect was present at 24 h but absent at 48 h after infection [25]. |
| T163 |
820-1006 |
Sentence |
denotes |
The difference between SARS-CoV2 and SARS-CoV in response to type I IFN treatment may be due to differences in structural proteins of these viruses, including NSP3, ORF3b, and ORF6 [25]. |
